CL2013003044A1 - Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de quinasa mps-1; composicion farmaceutica; procedimiento de preparacion; combinacion farmaceutica; compuestos intermediarios; y uso para la profilaxis o tratamiento de un tumor hematologico, un tumor solido y/o sus metastasis y leucemias, entre otras enfermedades. - Google Patents

Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de quinasa mps-1; composicion farmaceutica; procedimiento de preparacion; combinacion farmaceutica; compuestos intermediarios; y uso para la profilaxis o tratamiento de un tumor hematologico, un tumor solido y/o sus metastasis y leucemias, entre otras enfermedades.

Info

Publication number
CL2013003044A1
CL2013003044A1 CL2013003044A CL2013003044A CL2013003044A1 CL 2013003044 A1 CL2013003044 A1 CL 2013003044A1 CL 2013003044 A CL2013003044 A CL 2013003044A CL 2013003044 A CL2013003044 A CL 2013003044A CL 2013003044 A1 CL2013003044 A1 CL 2013003044A1
Authority
CL
Chile
Prior art keywords
compounds
tumor
mps
triazolo
leukemias
Prior art date
Application number
CL2013003044A
Other languages
English (en)
Spanish (es)
Inventor
Gerhard Siemeister
Antje Margret Wengner
Volker Schulze
Dirk Kosemund
Hartmut Schirok
Hans Briem
Detlef Stockigt
Philip Lienau
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of CL2013003044A1 publication Critical patent/CL2013003044A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2013003044A 2011-04-21 2013-10-21 Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de quinasa mps-1; composicion farmaceutica; procedimiento de preparacion; combinacion farmaceutica; compuestos intermediarios; y uso para la profilaxis o tratamiento de un tumor hematologico, un tumor solido y/o sus metastasis y leucemias, entre otras enfermedades. CL2013003044A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11163342 2011-04-21
EP11167872 2011-05-27

Publications (1)

Publication Number Publication Date
CL2013003044A1 true CL2013003044A1 (es) 2014-05-02

Family

ID=46124297

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013003044A CL2013003044A1 (es) 2011-04-21 2013-10-21 Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de quinasa mps-1; composicion farmaceutica; procedimiento de preparacion; combinacion farmaceutica; compuestos intermediarios; y uso para la profilaxis o tratamiento de un tumor hematologico, un tumor solido y/o sus metastasis y leucemias, entre otras enfermedades.

Country Status (39)

Country Link
US (1) US20140120087A1 (https=)
EP (1) EP2699575B1 (https=)
JP (1) JP5989091B2 (https=)
KR (1) KR20140025470A (https=)
CN (1) CN103608350B (https=)
AP (1) AP3491A (https=)
AR (1) AR086191A1 (https=)
AU (1) AU2012244859B2 (https=)
CA (1) CA2833657A1 (https=)
CL (1) CL2013003044A1 (https=)
CO (1) CO6801751A2 (https=)
CR (1) CR20130539A (https=)
CY (1) CY1116439T1 (https=)
DK (1) DK2699575T3 (https=)
DO (1) DOP2013000244A (https=)
EA (1) EA023766B1 (https=)
EC (1) ECSP13013011A (https=)
ES (1) ES2539265T3 (https=)
GT (1) GT201300254A (https=)
HR (1) HRP20150517T1 (https=)
HU (1) HUE025496T2 (https=)
IL (1) IL228704A0 (https=)
JO (1) JO3040B1 (https=)
MA (1) MA35049B1 (https=)
ME (1) ME02143B (https=)
MX (1) MX348783B (https=)
MY (1) MY164939A (https=)
PE (1) PE20141351A1 (https=)
PH (1) PH12013502169A1 (https=)
PL (1) PL2699575T3 (https=)
PT (1) PT2699575E (https=)
RS (1) RS54044B1 (https=)
SA (1) SA112330466B1 (https=)
SG (1) SG194003A1 (https=)
SI (1) SI2699575T1 (https=)
TW (1) TWI558703B (https=)
UY (1) UY34034A (https=)
WO (1) WO2012143329A1 (https=)
ZA (1) ZA201308707B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111841C2 (uk) 2011-04-21 2016-06-24 Гіліад Сайєнсіз, Інк. Сполуки бензотіазолу та їх фармацевтичне застосування
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
WO2013135612A1 (en) 2012-03-14 2013-09-19 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
SG11201408419QA (en) 2012-07-10 2015-01-29 Bayer Pharma AG Method for preparing substituted triazolopyridines
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
HK1222849A1 (zh) * 2013-06-07 2017-07-14 Bayer Pharma Aktiengesellschaft 具有作爲mps-1抑制剂的活性的取代的三唑并吡啶类
CA2914516A1 (en) * 2013-06-07 2014-12-11 Bayer Pharma Aktiengesellschaft Substituted triazolopyridines
HK1219737A1 (zh) * 2013-06-10 2017-04-13 Bayer Pharma Aktiengesellschaft 用於治疗癌症的新化合物
TN2015000543A1 (en) * 2013-06-11 2017-04-06 Bayer Pharma AG Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor
AP2015008898A0 (en) 2013-06-11 2015-12-31 Bayer Pharma AG Prodrug derivatives of substituted triazolopyridines
EP2860177A3 (en) 2013-09-20 2015-06-10 Bayer Intellectual Property GmbH Synthesis of functionalized arenes
ES2966392T3 (es) 2015-04-17 2024-04-22 Crossfire Oncology Holding B V Biomarcadores pronósticos para quimioterapia inhibidora de TTK
AU2018233367B2 (en) * 2017-03-16 2021-08-12 Jiangsu Hengrui Medicine Co., Ltd. Heteroaryl[4,3-c]pyrimidine-5-amine derivative, preparation method therefor, and medical uses thereof
CA3137152A1 (en) 2019-04-18 2020-10-22 The Johns Hopkins University Substituted 2-amino-pyrazolyl-[1,2,4]triazolo[1,5a] pyridine derivatives and use thereof
EP3994132A1 (en) 2019-07-03 2022-05-11 Sumitomo Dainippon Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
AU2021362678A1 (en) 2020-10-13 2023-05-04 The Johns Hopkins University SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
ATE413167T1 (de) 2004-08-17 2008-11-15 Galderma Res & Dev Neuartige biaromatische ppar-rezeptoren aktivierende zusammensetzungen und ihre verwendung in kosmetischen oder pharmazeutischen zusammensetzungen
BRPI0716239A2 (pt) * 2006-08-30 2013-08-13 Cellzome Ltd derivados de triazol como inibidores de cinase
CA2693232A1 (en) * 2007-07-18 2009-01-22 Novartis Ag Bicyclic heteroaryl compounds and their use as kinase inhibitors
MX2010002115A (es) 2007-08-23 2010-06-01 Aztrazeneca Ab 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos .proliferativos.
CA2691448A1 (en) 2007-08-31 2009-03-05 Dominique Swinnen Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
AU2008328882A1 (en) * 2007-11-27 2009-06-04 Cellzome Limited Amino triazoles as PI3K inhibitors
SG173610A1 (en) 2009-02-13 2011-09-29 Fovea Pharmaceuticals Sa [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors
JP6168773B2 (ja) 2009-04-29 2017-07-26 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾキノキサリン
JP5728683B2 (ja) 2009-09-04 2015-06-03 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ チロシンスレオニンキナーゼ阻害剤としての置換アミノキノキサリン
EP2343297A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas

Also Published As

Publication number Publication date
CR20130539A (es) 2013-12-04
WO2012143329A1 (en) 2012-10-26
EA201301181A1 (ru) 2014-08-29
MX348783B (es) 2017-06-28
GT201300254A (es) 2015-09-01
CN103608350A (zh) 2014-02-26
CY1116439T1 (el) 2017-02-08
DK2699575T3 (da) 2015-06-22
HK1190398A1 (zh) 2014-07-04
ME02143B (me) 2015-10-20
PT2699575E (pt) 2015-07-29
MY164939A (en) 2018-02-15
SI2699575T1 (sl) 2015-10-30
PL2699575T3 (pl) 2015-08-31
UY34034A (es) 2012-11-30
TW201245194A (en) 2012-11-16
CO6801751A2 (es) 2013-11-29
PE20141351A1 (es) 2014-11-01
AP3491A (en) 2015-12-31
ES2539265T3 (es) 2015-06-29
CN103608350B (zh) 2015-11-25
US20140120087A1 (en) 2014-05-01
MA35049B1 (fr) 2014-04-03
RS54044B1 (sr) 2015-10-30
ZA201308707B (en) 2016-07-27
NZ616456A (en) 2015-09-25
JP2014511887A (ja) 2014-05-19
TWI558703B (zh) 2016-11-21
AP2013007182A0 (en) 2013-10-31
HRP20150517T1 (hr) 2015-06-19
EA023766B1 (ru) 2016-07-29
KR20140025470A (ko) 2014-03-04
PH12013502169A1 (en) 2014-01-13
EP2699575B1 (en) 2015-03-25
HUE025496T2 (en) 2016-04-28
CA2833657A1 (en) 2012-10-26
ECSP13013011A (es) 2013-12-31
DOP2013000244A (es) 2014-03-16
MX2013012289A (es) 2013-11-21
JP5989091B2 (ja) 2016-09-07
JO3040B1 (ar) 2016-09-05
SG194003A1 (en) 2013-11-29
EP2699575A1 (en) 2014-02-26
IL228704A0 (en) 2013-12-31
AR086191A1 (es) 2013-11-27
AU2012244859B2 (en) 2017-06-08
SA112330466B1 (ar) 2015-09-28
AU2012244859A1 (en) 2013-10-31

Similar Documents

Publication Publication Date Title
CL2013003044A1 (es) Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de quinasa mps-1; composicion farmaceutica; procedimiento de preparacion; combinacion farmaceutica; compuestos intermediarios; y uso para la profilaxis o tratamiento de un tumor hematologico, un tumor solido y/o sus metastasis y leucemias, entre otras enfermedades.
CL2013002430A1 (es) Compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de proteina kinasa trk; composicion farmaceutica; compuesto intermediarios; utiles para el tratamiento de carcinoma pailar de tiroides, cancer de pancreas, cancer de colon y carcinoma de mama, entre otras.
MX2019003605A (es) Formas solidas de un inhibidor de cdk4/6 selectivo.
CL2014001103A1 (es) Compuestos derivados de heteroaril piridona y aza-piridona sustituidas, inhibidores de btk quinasa; composicion farmaceutica que los comprende; proceso de preparacion de la composicion farmaceutica; kit farmaceutico; y uso para el tratamiento de trastornos inmunes, cancer, inflamacion, trastornos neurologicos, entre otros.
HUE061909T2 (hu) Pirazolo[1,5-a]pirimidinek alkalmazása ATR kináz inhibítorként, rákos megbetegedések kezelésére
HUE053067T2 (hu) Helyettesített pirazolo[1,5-A]piridin vegyületek, mint RET kináz inhibitorok
ZA201700035B (en) Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
CL2014000543A1 (es) Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer.
SI3077397T1 (sl) 2-amino-6-fluoro-N-(5-fluoro-piridin-3-IL)pirazolo(1,5-A)pirimidin-3- karboksamidna spojina, koristna kot inhibitor kinaze ATR, njena priprava, različne trdne oblike in njeni radioaktivno označeni derivati
CL2013003051A1 (es) Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio
HK1210775A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
EA201491456A1 (ru) Соединения-ингибиторы raf
IL231591A0 (en) Converted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases
DK3489238T3 (da) Farmaceutiske sammensætninger af 6h-pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-on- og [1,2,4]triazolo[1,5-c]pteridin-5(6h)-on-derivater som pde1-inhibitorer til behandling af for eksempel neurologiske lidelser
BR112012023660B8 (pt) usos de uma quantidade terapeuticamente eficaz de um composto, ou de um sal, solvato, hidrato ou pró-fármaco farmaceuticamente aceitável do mesmo para o tratamento de câncer
CL2014001060A1 (es) Compuestos derivados de aril-quinolina; proceso de obtencion; composicion farmaceutica que los comprende y uso en el tratamiento o profilaxis de la diabetes tipo 2, la aterosclerosis, cancer, entre otras enfermedades.
CL2015000408A1 (es) Compuestos derivados de pirazolo[4,3-d]pirimidina y sus sales; composicion farmaceutica que los comprende, util para el tratamiento de enfermedades alergicas, inflamatorias, infecciosas o cancer.
HUE057317T2 (hu) Helyettesített [1,2,4]triazolo[1,5-A]pirimidin-7-IL vegyületeket tartalmazó készítmények mint PDE2 inhibítorok
PT3177659T (pt) Compostos contendo azoto, adequados para uso na preparação de poliuretanos
CL2014000203A1 (es) Compuestos derivados de piridin-2(1h) -ona, inhibidores de jak; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento de enfermedades mieloproliferativas, leucemia,artritid reumatoide, asma, esclerosis multiplem, entre otras.
CL2014000849A1 (es) Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas.
CR20170315A (es) Inhibridores bace 1 selectivos
EP2861608B8 (en) Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
EA201490283A1 (ru) Соли азабициклических диариловых эфиров и способы их получения или получения их предшественников
WO2013188750A3 (en) Substituted macrocyclic compounds having proteasome inhibitory activity